The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The use of regional anesthesia in breast surgery improves the postoperative outcome, reduces the development of infection, and weakens the perioperative immunosuppressive response associated with the response to surgical stress. The investigators hypothesize that the use of propofol / paravertebral anesthesia and analgesia will be accompanied by a decrease in serum proinflammatory cytokines and/or an increase in anti-inflammatory cytokines compared to propofol / PECS 2 anesthesia and analgesia. The research will be on 100 respondents divided into two groups. 0.5% levobupivacaine will be administered to both groups. Serum concentrations of pro- and anti-inflammatory cytokines, and lymphocyte subpopulations 1h before, 24h, and 48h after surgery will be measured. The investigators aim to compare the effect of propofol / paravertebral and propofol / PECS 2 anesthesia and analgesia on serum perioperative values of pro-inflammatory and anti-inflammatory cytokines to standardize protocols and apply the best method of perioperative analgesia in breast cancer surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rijeka
• Treatments: Anesthetics; Levobupivacaine

Criteria

Inclusion Criteria:

• quadrantectomy with equilateral axillary lymphadenectomy

• anesthesia preoperative status (American Society of Anesthesiologists (ASA)) 1 and 2

Exclusion Criteria:

• patient rejection

• ASA> 3

• contraindication for local anesthetic

• contraindications for planned regional anesthesia and analgesia

• immunosuppressive therapy including corticosteroids

• acute infection

• history of chronic opioid use

• presence of autoimmune disease

• obese definite body mass index BMI) greater than 29.9 kg/m2